中国大陆医生抗HCV治疗现状调查

发布时间：2018-03-22 17:13

本文选题：HCV　切入点：治疗　出处：《重庆医科大学学报》2017年07期 　论文类型：期刊论文

【摘要】：目的:丙型肝炎病毒感染是严重的全球公共卫生问题。在中国,丙肝感染者约为1 000万人。全面了解我国医生对丙肝抗病毒知识的掌握治疗现状,有助于进一步提高患者治愈率。方法:2015年7月至2016年6月,对全国(除港、澳、台外)27个省市自治区56家医院的560名医生,就对丙肝的知晓情况、抗病毒药物的选择、抗病毒治疗疗程的影响因素、对直接抗病毒药物的了解情况等方面,进行了调研。结果:共收回有效调查问卷502份。研究对象中女性略多于男性,平均年龄为37岁;纳入的医生所在科室中,肝病科医生所占比例最高,达43.6%,其次是感染科(38%)。在丙肝抗病毒治疗药物的选择过程中,93%的医生会首选长效干扰素+利巴韦林。在影响医生决定抗病毒疗程的因素中,只有28.6%医生会考虑到基线病毒载量对疗程的影响。对于抗病毒治疗的治愈指标,高达64.9%的医生对于长效干扰素联合利巴韦林(P/R)治疗后SVR的准确概念尚不清楚。而且在丙肝治疗过程中,当未实现快速病毒学应答(RVR)时,高达93%的医生选择终止治疗。有77%的医生知道DAAs,不同科室医生对DAAs的知晓情况具有统计学差异(P0.001)。结论:中国大陆部分医生抗HCV治疗尚有不规范之处,亟需培训和提高。
[Abstract]:Objective: hepatitis C virus infection is a serious global public health problem. In China, there are about 1 0 people infected with hepatitis C. Methods: from July 2015 to June 2016, 560 doctors in 56 hospitals in 27 provinces, municipalities and autonomous regions across the country (excluding Hong Kong, Macao, Taiwan) were informed about hepatitis C and the choice of antiviral drugs. The factors influencing the course of antiviral therapy and the understanding of direct antiviral drugs were investigated. Results: 502 effective questionnaires were collected. The average age of the subjects was 37 years old. Of the departments in which doctors are included, the proportion of doctors with liver diseases is the highest. 43.6, followed by infection. 93% of doctors will choose long-acting interferon ribavirin in the selection of antiviral drugs for hepatitis C. among the factors that affect the doctor's decision on the course of antiviral treatment, Only 28.6 percent of doctors take into account the effect of baseline viral load on the course of treatment. Up to 64.9% of doctors are not clear about the exact concept of SVR after long-acting interferon plus ribavirin P / R, and in the course of hepatitis C treatment, when the rapid virological response is not realized, Up to 93% of the doctors chose to terminate the treatment, 77% of the doctors knew about DAAs.There were statistical differences in the knowledge of DAAs among doctors in different departments. Conclusion: some doctors in mainland China still have some irregularities in the treatment of HCV, which needs training and improvement.
【作者单位】：首都医科大学附属北京佑安医院人工肝中心;吴阶平医学基金会肝病医学部;
【分类号】：R512.63

【相似文献】